AAPL343.37+3.29 (+0.97%) ▲|ABBV265.81+2.61 (+0.99%) ▲|ABT108.74+1.47 (+1.37%) ▲|ACN174.95+10.29 (+6.25%) ▲|ADBE264.54+15.36 (+6.16%) ▲|AMAT450.72-25.74 (-5.40%) ▼|AMD438.41-16.21 (-3.57%) ▼|AMGN389.84-3.26 (-0.83%) ▼|AMT173.52+2.02 (+1.18%) ▲|AMZN231.30+0.44 (+0.19%) ▲|AVGO377.12-3.80 (-1.00%) ▼|AXP333.13-3.51 (-1.04%) ▼|BA215.89-5.68 (-2.56%) ▼|BAC61.60-1.03 (-1.64%) ▼|BKNG204.03+4.72 (+2.37%) ▲|BLK1,098.17+0.62 (+0.06%) ▲|BMY63.67+0.07 (+0.10%) ▲|BNY153.55-2.95 (-1.88%) ▼|BRK-B510.63-1.75 (-0.34%) ▼|C127.65-4.83 (-3.64%) ▼|CAT781.26-59.60 (-7.09%) ▼|CL93.31+0.58 (+0.62%) ▲|CMCSA24.85+0.66 (+2.71%) ▲|COF210.38-2.03 (-0.96%) ▼|COP118.22+4.12 (+3.61%) ▲|COST974.80+8.22 (+0.85%) ▲|CRM189.06+7.56 (+4.17%) ▲|CSCO114.03-1.56 (-1.35%) ▼|CVS106.54-2.80 (-2.56%) ▼|CVX191.72+4.14 (+2.21%) ▲|DE614.72-25.13 (-3.93%) ▼|DHR198.11-0.94 (-0.47%) ▼|DIS98.89+0.00 (+0.00%) ▲|DUK129.38+0.14 (+0.11%) ▲|EMR146.87-4.94 (-3.25%) ▼|FDX309.34-3.31 (-1.06%) ▼|GD388.52-4.67 (-1.19%) ▼|GE353.79-9.80 (-2.70%) ▼|GEV906.96-36.42 (-3.86%) ▼|GILD134.43+0.11 (+0.08%) ▲|GM91.16+0.86 (+0.95%) ▲|GOOG338.98+6.38 (+1.92%) ▲|GOOGL339.83+6.12 (+1.83%) ▲|GS991.09-42.25 (-4.09%) ▼|HD340.69-3.78 (-1.10%) ▼|HON243.80-3.26 (-1.32%) ▼|IBM228.83+1.28 (+0.56%) ▲|INTC83.98-2.32 (-2.69%) ▼|INTU335.65+22.66 (+7.24%) ▲|ISRG354.36-7.44 (-2.06%) ▼|JNJ266.31-0.42 (-0.16%) ▼|JPM347.40-9.92 (-2.77%) ▼|KO89.12+0.85 (+0.96%) ▲|LIN511.51+0.33 (+0.06%) ▲|LLY1,218.56-2.11 (-0.17%) ▼|LMT576.19-5.12 (-0.88%) ▼|LOW217.71-0.53 (-0.24%) ▼|LRCX258.45-11.16 (-4.14%) ▼|MA566.34+3.59 (+0.64%) ▲|MCD272.04-0.99 (-0.36%) ▼|MDLZ65.20+2.72 (+4.35%) ▲|MDT87.62+0.74 (+0.85%) ▲|META593.40-0.02 (0.00%) ▼|MMM179.43-3.05 (-1.67%) ▼|MO75.17+0.35 (+0.47%) ▲|MRK131.08-0.74 (-0.56%) ▼|MS204.67-6.91 (-3.27%) ▼|MSFT398.10+4.75 (+1.21%) ▲|MU763.76-56.78 (-6.92%) ▼|NEE88.83-0.45 (-0.50%) ▼|NFLX73.58+1.19 (+1.64%) ▲|NKE43.17+0.12 (+0.27%) ▲|NOW116.38+5.76 (+5.21%) ▲|NVDA192.84-4.17 (-2.12%) ▼|ORCL119.28-0.69 (-0.57%) ▼|PEP144.34+1.48 (+1.04%) ▲|PFE25.20-0.06 (-0.22%) ▼|PG145.07-3.82 (-2.56%) ▼|PLTR125.19+1.66 (+1.34%) ▲|PM199.72-0.46 (-0.23%) ▼|QCOM160.70-2.19 (-1.34%) ▼|RTX218.92+0.34 (+0.16%) ▲|SBUX104.02+0.92 (+0.89%) ▲|SCHW105.62-0.35 (-0.33%) ▼|SO96.21-0.57 (-0.59%) ▼|SPG237.38+0.68 (+0.29%) ▲|T24.33-0.34 (-1.36%) ▼|TMO571.53-4.88 (-0.85%) ▼|TMUS182.00-0.39 (-0.21%) ▼|TSLA302.43-5.01 (-1.63%) ▼|TXN275.59-1.49 (-0.54%) ▼|UBER71.36+0.62 (+0.88%) ▲|UNH421.63-7.16 (-1.67%) ▼|UNP291.27-3.18 (-1.08%) ▼|UPS104.26-1.28 (-1.21%) ▼|USB63.17-1.26 (-1.96%) ▼|V368.81+2.22 (+0.61%) ▲|VZ48.40+0.21 (+0.43%) ▲|WFC84.44-2.43 (-2.80%) ▼|WMT114.08+0.98 (+0.87%) ▲|XOM156.55+3.51 (+2.29%) ▲|AAPL343.37+3.29 (+0.97%) ▲|ABBV265.81+2.61 (+0.99%) ▲|ABT108.74+1.47 (+1.37%) ▲|ACN174.95+10.29 (+6.25%) ▲|ADBE264.54+15.36 (+6.16%) ▲|AMAT450.72-25.74 (-5.40%) ▼|AMD438.41-16.21 (-3.57%) ▼|AMGN389.84-3.26 (-0.83%) ▼|AMT173.52+2.02 (+1.18%) ▲|AMZN231.30+0.44 (+0.19%) ▲|AVGO377.12-3.80 (-1.00%) ▼|AXP333.13-3.51 (-1.04%) ▼|BA215.89-5.68 (-2.56%) ▼|BAC61.60-1.03 (-1.64%) ▼|BKNG204.03+4.72 (+2.37%) ▲|BLK1,098.17+0.62 (+0.06%) ▲|BMY63.67+0.07 (+0.10%) ▲|BNY153.55-2.95 (-1.88%) ▼|BRK-B510.63-1.75 (-0.34%) ▼|C127.65-4.83 (-3.64%) ▼|CAT781.26-59.60 (-7.09%) ▼|CL93.31+0.58 (+0.62%) ▲|CMCSA24.85+0.66 (+2.71%) ▲|COF210.38-2.03 (-0.96%) ▼|COP118.22+4.12 (+3.61%) ▲|COST974.80+8.22 (+0.85%) ▲|CRM189.06+7.56 (+4.17%) ▲|CSCO114.03-1.56 (-1.35%) ▼|CVS106.54-2.80 (-2.56%) ▼|CVX191.72+4.14 (+2.21%) ▲|DE614.72-25.13 (-3.93%) ▼|DHR198.11-0.94 (-0.47%) ▼|DIS98.89+0.00 (+0.00%) ▲|DUK129.38+0.14 (+0.11%) ▲|EMR146.87-4.94 (-3.25%) ▼|FDX309.34-3.31 (-1.06%) ▼|GD388.52-4.67 (-1.19%) ▼|GE353.79-9.80 (-2.70%) ▼|GEV906.96-36.42 (-3.86%) ▼|GILD134.43+0.11 (+0.08%) ▲|GM91.16+0.86 (+0.95%) ▲|GOOG338.98+6.38 (+1.92%) ▲|GOOGL339.83+6.12 (+1.83%) ▲|GS991.09-42.25 (-4.09%) ▼|HD340.69-3.78 (-1.10%) ▼|HON243.80-3.26 (-1.32%) ▼|IBM228.83+1.28 (+0.56%) ▲|INTC83.98-2.32 (-2.69%) ▼|INTU335.65+22.66 (+7.24%) ▲|ISRG354.36-7.44 (-2.06%) ▼|JNJ266.31-0.42 (-0.16%) ▼|JPM347.40-9.92 (-2.77%) ▼|KO89.12+0.85 (+0.96%) ▲|LIN511.51+0.33 (+0.06%) ▲|LLY1,218.56-2.11 (-0.17%) ▼|LMT576.19-5.12 (-0.88%) ▼|LOW217.71-0.53 (-0.24%) ▼|LRCX258.45-11.16 (-4.14%) ▼|MA566.34+3.59 (+0.64%) ▲|MCD272.04-0.99 (-0.36%) ▼|MDLZ65.20+2.72 (+4.35%) ▲|MDT87.62+0.74 (+0.85%) ▲|META593.40-0.02 (0.00%) ▼|MMM179.43-3.05 (-1.67%) ▼|MO75.17+0.35 (+0.47%) ▲|MRK131.08-0.74 (-0.56%) ▼|MS204.67-6.91 (-3.27%) ▼|MSFT398.10+4.75 (+1.21%) ▲|MU763.76-56.78 (-6.92%) ▼|NEE88.83-0.45 (-0.50%) ▼|NFLX73.58+1.19 (+1.64%) ▲|NKE43.17+0.12 (+0.27%) ▲|NOW116.38+5.76 (+5.21%) ▲|NVDA192.84-4.17 (-2.12%) ▼|ORCL119.28-0.69 (-0.57%) ▼|PEP144.34+1.48 (+1.04%) ▲|PFE25.20-0.06 (-0.22%) ▼|PG145.07-3.82 (-2.56%) ▼|PLTR125.19+1.66 (+1.34%) ▲|PM199.72-0.46 (-0.23%) ▼|QCOM160.70-2.19 (-1.34%) ▼|RTX218.92+0.34 (+0.16%) ▲|SBUX104.02+0.92 (+0.89%) ▲|SCHW105.62-0.35 (-0.33%) ▼|SO96.21-0.57 (-0.59%) ▼|SPG237.38+0.68 (+0.29%) ▲|T24.33-0.34 (-1.36%) ▼|TMO571.53-4.88 (-0.85%) ▼|TMUS182.00-0.39 (-0.21%) ▼|TSLA302.43-5.01 (-1.63%) ▼|TXN275.59-1.49 (-0.54%) ▼|UBER71.36+0.62 (+0.88%) ▲|UNH421.63-7.16 (-1.67%) ▼|UNP291.27-3.18 (-1.08%) ▼|UPS104.26-1.28 (-1.21%) ▼|USB63.17-1.26 (-1.96%) ▼|V368.81+2.22 (+0.61%) ▲|VZ48.40+0.21 (+0.43%) ▲|WFC84.44-2.43 (-2.80%) ▼|WMT114.08+0.98 (+0.87%) ▲|XOM156.55+3.51 (+2.29%) ▲|
26.8 C
New York
Wednesday, July 29, 2026

Tag: immune system

newssourceFORcompanyinformationcontent1releasesmarket

Titan of Industry Allan Camaisa Teams Up with Res Nova Bio to Advance Breast Cancer Immunotherapy

Clinical Stage Biotechnology Company Uses Patient Immune System to "Seek and Destroy" Cancer and Metastasis SAN DIEGO, Aug. 1, 2025 /PRNewswire/ -- Res Nova Biologics,...

Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets

SAN FRANCISCO, July 31, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter on Thursday, August 7, 2025, after the...

Press release: Online availability of Sanofi’s half-year financial report for 2025


Online availability of Sanofi’s half-year financial report for 2025

Espervita’s EVT0185 Shows Dramatic Tumor Reduction and Immune Activation in Preclinical MASH-Driven Hepatocellular Carcinoma

ANN ARBOR, Mich., July 30, 2025 /PRNewswire/ -- Espervita Therapeutics, a biotechnology company developing targeted metabolic reprogramming therapies, announced the publication in Nature featuring groundbreaking...

Dr. Falk Pharma and Allianthera (Suzhou) Biopharmaceuticals Forge Strategic Partnership for Novel AhR Agonist Development

Freiburg (Germany), Suzhou (China) and Boston (USA), July 30, 2025: 

Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved...

Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved...

BlueSphere Bio CSO Alan Korman Recipient of Esteemed 2025 William B. Coley Award

Alan Korman honored in the category of tumor immunology for foundational role in checkpoint inhibitors PITTSBURGH, July 29, 2025 /PRNewswire/ -- BlueSphere Bio, a clinical...

LIfT BioSciences announces grant of €12 million from Ireland’s Disruptive Technologies Innovation Fund to support the first-in-human clinical trial of LIfT’s IMAN therapy

FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older

WALTHAM, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved EMPAVELI® (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older, to reduce proteinuria. C3G and primary IC-MPGN are rare kidney diseases, affecting 5,000 people in the United States.1

BATMAN brings TCR therapy out of the shadows

COLD SPRING HARBOR, N.Y., July 28, 2025 /PRNewswire/ -- Imagine your immune cells could be modified to attack any kind of cancer. T cell...

Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025

Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025

POP BIO and CEPI announce collaboration for faster responses to Disease X

Buffalo, NY, July 25, 2025 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a biotechnology company specializing in nanoparticle-based vaccines, and the Coalition for Epidemic Preparedness Innovations (CEPI) have announced a new collaboration to accelerate the development of vaccines against future pandemic threats, including a potential ‘Disease X’. Backed by up to $1.5 million in funding from CEPI, the partnership will advance POP BIO’s SNAP™ (Spontaneous Nanoliposome Antigen Particleization) platform—a plug-and-play technology designed to enable rapid-response vaccine development through streamlined protein purification and nanoparticle delivery.

Kisses from Sicily: refreshing mocktails with PGI Syracuse Lemon

Summer ignites a desire for freshness, lightness, and authentic flavors: the stars of the season are non-alcoholic cocktails made with PGI Syracuse Lemon, an explosion of aromas and tastes that embody the authenticity of Sicily. Among these, the Dracula Kiss stands out for its originality and taste, a mocktail inspired by the legendary figure of Vlad Țepeș, a perfect balance between mystique and Mediterranean flavor! 
Summer ignites a desire for freshness, lightness, and authentic flavors: the stars of the season are non-alcoholic cocktails made with PGI Syracuse Lemon, an explosion of aromas and tastes that embody the authenticity of Sicily. Among these, the Dracula Kiss stands out for its originality and taste, a mocktail inspired by the legendary figure of Vlad Țepeș, a perfect balance between mystique and Mediterranean flavor!

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsImmune system

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers